1Rowley JD. The Philadelphia chromosome trartslocation. A paradigm for understanding leukemia [J]. Cancer, 1990(65 ) :2178-2184.
2Guo JQ, Lian JY, Xian YM, Lee M-S, Deisseroth AB, Stass SA, Champ- lin RE, Talpas M, Wang JYJ, Arlinghaus RB. BCR-ABL protein ex- pression in peripheral blood cells of chronic myelogenous leukemia pa- tients undergoing therapy[J]. Blood, 1994, (83) :3629-3637.
3Pastemak G, Hochhaus A Schultheis B, Hehlmann 1L Chronic myelog- enous leukemia:molecular and cellular aspects[J]. J Cancer Res Clin Oncol, 1998 (124) :643-660.
4Groffcn J, Morris C, Heisterkamp N. Philadelphia chromosome translo- cation In Deisseroth AB, Arlinghaus RB (eds) Ghronic myelogenous leukemia[ J]. Dekker, New York, 181-209.
5Witte On. Role of the BCR-ABL oncogene in human leukemia: Fif- teenth Richard and Hilda Rosenthal Foundation award lecture [J]. Cancer Res,1993, (53) :485.
6Heisterkamp N, Stcphenson JR., Groffen J, et al. Localization of the c- abl oncogene adjacent to a translocation break point in chronic myelo- cytic leukaemia[J]. Nature, 1983,306:239-242.
8Gorre ME, Sawyer CL Molecular mechanisms of resistance to ST1571 in chronic myeloid leukemia [J]. Curt Opin Hematol, 2002,9 ( 4 ) : 303-307.
9COHEN M H ,WILLIAMS G,JOHNSON J R,et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous [J].
10Okuda K,Weisberg E, Gilliland DG, et al. ARG tyrosine kinase activ- ity is inhibited by STI571 [J]. Blood,2001,97(8) :2440-2448.
二级参考文献54
1Guilhot F.Sustained durability of responses plus high rates ofcytogenetic responses result in long-germ benefit for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib (IM) therapy[J].Blood,2004,104:21.
2Grisvold D,Bumm T,O'Hare T,et al.Investigation of the biological differences between bcr/abl kinase mutations resistant to imatinib[J].Blood,2004,104:555.
3Donato N J,Wu J Y,Stapley J,et al.Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia[J].Cancer Res,2004,64:672-677.
4Elrick L J,Jorgensen H G,Mountford J C,et al.Punish the parent not the progeny[J].Blood,2005,105:1862-1865.
5O'Hare T,Wahers D K,Stoffregen E P,et al.In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants[J].Cancer Res,2005,65(11):4500-4505.
6Kantarjian H,Giles F,Wunderle L,et al.Nilotinib in imatinibresistant CML and Philadelphia chromosome-positive ALL[J].N Engl J Med,2006,354(24):2542-2551.
7Yezhelyev M V,Koehl G,Guba M,et al.Inhibition of Src tyrosine kinase as a treatment for human pancreatic cancer growing orthotopically in nude mice[J].Clin Cancer Res,2004,10(23):8028-8036.
8Donato N J,Wu J Y,Stapley J,et al.BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to ST1571[J].Blood,2003,101 (2):690-698.
9Shah N P,Tran C,Lee F Y,et al.Overriclingimatinib resistance with a novel ABL kinase inhihitor[J].Science,2004,305 (5682):399-401.
10Tokarski J S,Newitt J A,Chang C Y.et al.The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants[J].Cancer Res,2006,66 (11):5790-5797.
